Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574858 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of QRH-882260 Heptapeptide
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02574858 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 25 participants.
The verdict
NCT02574858, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of orally administered QRH-882260, a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR).
Interventions
- DRUG QRH-882260
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02574858
The ClinicalTrials.gov registry entry for NCT02574858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QRH-882260 is the first listed.
NCT02574858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02574858 about?
NCT02574858 is a clinical study titled "Study of the Safety of QRH-882260 Heptapeptide". The purpose of this study is to evaluate the safety of orally administered QRH-882260, a topically administered Cy5-labeled heptapeptide specific for epithelial growth factor receptor (EGFR).
What is the current status of trial NCT02574858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02574858?
The interventions under investigation include: QRH-882260 (DRUG).
Who is sponsoring clinical trial NCT02574858?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.